Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration

@article{Hurley2008CosteffectivenessOR,
  title={Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration},
  author={Susan F Hurley and Jane Matthews and Robyn H. Guymer},
  journal={Cost Effectiveness and Resource Allocation : C/E},
  year={2008},
  volume={6},
  pages={12 - 12}
}
BACKGROUND Intravitreal ranibizumab prevents vision loss and improves visual acuity in patients with neovascular age-related macular degeneration, but it is expensive, and efficacy beyond 2 years is uncertain. METHODS We assessed the cost-effectiveness of ranibizumab compared with no ranibizumab over 10 years, using randomized trial efficacy data for the first 2 years, post-trial efficacy assumptions, and ranibizumab acquisition costs ranging from the wholesale price ($1,950 per dose) to the… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
13 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

GDP PPPs and Derived Indices for all OECD countries

  • MC Gillies, TY Wong
  • 2008

Similar Papers

Loading similar papers…